WuXi Biologics (Cayman) Inc. announced that its Drug Product Facility 5 (DP5) and Drug Product Packaging Center (DPPC) in Wuxi have received Good Manufacturing Practice (GMP) certifications from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the commercial manufacturing of an ophthalmic biologic. The certification follows a four-day inspection with no critical findings. WuXi Biologics provides end-to-end manufacturing services for this product, covering both drug substance and drug product. As of the end of 2025, WuXi Biologics has passed 46 regulatory inspections and obtained 136 facility license approvals, maintaining a 100% pass rate for FDA Pre-License Inspections. The company operates 15 GMP-certified drug substance and drug product facilities within its global network.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN61899) on January 13, 2026, and is solely responsible for the information contained therein.